Best of ASCO - 2014 Annual Meeting

 

Welcome

Non-Hodgkin Lymphoma

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Pd-l1 gene alterations to identify a subset of diffuse large B cell lymphoma that harbor a T cell inflamed phenotype.

James K. Godfrey

7566

90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.

Mariano Provencio-Pulla

7550

A basal gene expression signature to predict for synergy of combined EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.

Jennifer Kimberly Lue

7546

A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.

Amrita Y. Krishnan

TPS7586

A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.

Simon Rule

TPS7588

A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).

Herve Tilly

TPS7589

A phase II trial of bevacizumab-GemAOD regimen for newly diagnosed extranodal NK/T cell lymphoma.

Zhiming Li

7564

A phase III open label randomized study to compare the efficacy of lenalidomide-rituximab vs bendamustine-rituximab in treatment naive follicular lymphoma.

Susanta Kumar Paikaray

e19552

A population-based evaluation of demographics and survival in primary effusion lymphoma: SEER database analysis.

John Khoury

e19535

A proposal for a new staging system for extranodal natural killer T-cell lymphoma, nasal type, to predict the treatment strategy: A multicentre study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.

Tongyu Lin

7552

A retrospective study of double-hit lymphomas in elderly patients (> 70 years): Overall outcomes.

Christie Hancock

e19530

A retrospective study of the treatment-associated mortality of the patients with primary ocular adnexal mucosa-associated lymphoid tissue lymphoma after the molecular and immunological diagnosis.

Yuya Masuda

e19534

Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).

Nathan Hale Fowler

7549

Acalabrutinib combined with PI3Kδ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.

Paul M. Barr

7518

Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).

Roger Owen

7501

Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Martin JS Dyer

7547

Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.

Ranjana H. Advani

7504

AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL.

Juan Carlos Ramos

7573

Baseline PET-CT functional parameters to identify low-grade versus grade 3A follicular lymphoma.

Ajay Major

e19541

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) registry data.

Corinne Haioun

7554

Characterization of the immunogenomic landscape of follicular lymphoma.

Paola Dama

e19531

Circulating tumor DNA to predict timing of relapse in mantle cell lymphoma.

Mark J. Roschewski

7576

Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.

Martin H. Dreyling

7570

Current trends and inpatient outcomes of venous thromboembolism-related admissions among patients with diffuse large B-cell lymphoma: A Nationwide Inpatient Sample Database analysis.

Xavier Alberto Andrade Gonzalez

e19546

Delayed subspecialist referral in diffuse large B-cell lymphoma: Predictive factors and impact on disease status and mortality.

Joanna Zurko

e19524

DEVEC metronomic schedule for aggressive B and T-cell lymphomas.

Maria Christina COX

7563

Discover BCL6 translocations partner gene in diffuse large b-cell lymphoma by target-captured next generation sequencing.

Hui Zhou

e19527

DLBCL in Hispanics: The University of Miami (UM) experience.

Moises Harari Turquie

e19526

DLBCL outcomes in Malawi: Effect of HIV and derivation of a simplified prognostic score.

Matthew Painschab

7565

Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study.

Kana Miyazaki

7561

Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA.

Joanne Soo

7572

Effects of bendamustine, bortezomib, and rituximab on 1-year survival rates in elderly patients newly diagnosed with mantle cell lymphoma.

Shuangshuang Fu

e19537

Efficacy of up-front hematopoietic cell transplantation in peripheral t-cell lymphoma, not otherwise specified (PTCL-NOS): A National Cancer Database analysis.

Bhagirathbhai R. Dholaria

7578

Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.

Jordan Gauthier

7567

Genetic analysis of diffuse large B-cell lymphoma occurring in cases with antecedent Waldenström macroglobulinaemia.

Dipti Talaulikar

e19544

High RDW as a predictive and prognostic factor in patients with diffuse large B-cell lymphoma treated with chemoimmunotherapy.

Sally Paredes

e19547

Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study.

Christophe Marc Bonnet

e19550

ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.

Michael Brady

TPS7587

Impact of histologic type on survival in primary testicular lymphomas.

Taha Al-Juhaishi

e19545

Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Jacob Drobnyk Soumerai

7519

Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.

Tongyu Lin

7553

Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials.

Alessia Castellino

7562

Multi-center retrospective study evaluating outcomes of grade 3A follicular lymphoma (FL).

Kyle Greene

7551

Novel formulation of cannabinoid analogues used in cancer therapy.

Tori Strong

e19536

Outcome of young patients with blastoid variant mantle cell lymphoma: An analysis of 138 patients.

James Gerson

e19548

Outcomes in newly diagnosed diffuse large B cell lymphoma presenting with hepatic and/ or renal dysfunction.

Srinivasa Reddy Sanikommu

7558

Outcomes in patients with marginal zone lymphomas undergoing transformation to high-grade lymphomas.

Juan Pablo Alderuccio

7559

Outcomes of patients with MYC-expressing aggressive B cell non-Hodgkin lymphomas who fail two or more lines of therapy.

Daniel Jeffrey Landsburg

e19528

Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL).

Chadi Nabhan

7545

Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

Connie Lee Batlevi

7520

Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma.

Stefan K. Barta

7568

Predictors of disease progression in smoldering Waldenström macroglobulinemia.

Saurabh Zanwar

7571

Predictors of early vs late diffuse large B cell lymphoma (DLBCL) relapses in the Rituximab era.

Jasmin Jiemin Koh

e19553

Primary non-Hodgkin lymphoma of testis: Clinical and morphological features.

Sotnikova Olga

e19523

Primary testicular lymphoma: Treatment patterns and survival of 1740 men from the National Cancer Database.

Fernando Caumont

7555

Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial.

Pierluigi Porcu

7577

Radiation therapy in primary testicular lymphoma (PTL): Does practice match the standard of care?

Thomas Ollila

7544

Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.

Michael Pfreundschuh

7574

Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.

Laurie Helen Sehn

7507

Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.

He Huang

7560

R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the “INGRID” phase II trial.

Andres J. Ferreri

7575

Relationship between MRD and PET responses and PFS in previously untreated follicular lymphoma in the GALLIUM trial.

Judith Trotman

7557

RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.

Nathan Hale Fowler

7500

Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

David Andorsky

7516

Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).

Grzegorz S. Nowakowski

7548

Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience.

Guldane Cengiz Seval

e19525

Risk and types of secondary primary malignancies in DLBCL survivors changes over time based on stage at diagnosis.

Ajay Major

e19540

Rituximab maintenance for mantle cell lymphoma: A meta-analysis.

Talal Hilal

e19557

Romidepsin activity in T follicular helper(TFH)-phenotype PTCL versus non TFH treated on the same clinical trials.

Paola Ghione

7509

Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.

Michelle A. Fanale

7580

Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.

Wenying Zhang

7556

Tenalisib, a dual PI3K δ/γ inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma.

Yasuhiro Oki

7510

The average relative dose intensity of R-CHOP as an independent prognostic factor determining overall survival in diffuse large B cell lymphoma patients.

Monika Długosz-Danecka

e19542

The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

Paul A. Hamlin

7511

The effect of duvelisib, a dual inhibitor of PI3K-δ,γ, on components of the tumor microenvironment in previously untreated follicular lymphoma.

Carla Casulo

7579

The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.

Ho Sup Lee

e19538

Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral t cell lymphoma (PTCL).

Steven M. Horwitz

e19532

Treatment approach for non-Hodgkin lymphoma patients since first biosimilars of rituximab approved in EU5.

Alessandra Franceschetti

112

Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).

Mathias J. Rummel

7515

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

Jeremy S. Abramson

7505

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

Olalekan O. Oluwole

TPS7585